Lifewise Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 03-11-2024
- Paid Up Capital ₹ 0.60 M
as on 03-11-2024
- Company Age 4 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.92 M
as on 03-11-2024
- Revenue 59.31%
(FY 2023)
- Profit 685.93%
(FY 2023)
- Ebitda 69.62%
(FY 2023)
- Net Worth 74.11%
(FY 2023)
- Total Assets 12.86%
(FY 2023)
About Lifewise Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.60 M.
The company currently has active open charges totaling ₹4.92 M.
Ravi Ranjan, Rakesh Sharma, and Shruti Rana serve as directors at the Company.
- CIN/LLPIN
U24297HR2020PTC090666
- Company No.
090666
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Nov 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Panchkula, Haryana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Lifewise Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravi Ranjan  | Director | 04-Nov-2020 | Current |
| Rakesh Sharma | Director | 04-Nov-2020 | Current |
| Shruti Rana | Director | 04-Nov-2020 | Current |
Financial Performance of Lifewise Pharmaceuticals.
Lifewise Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 59.31% increase. The company also saw a substantial improvement in profitability, with a 685.93% increase in profit. The company's net worth Soared by an impressive increase of 74.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lifewise Pharmaceuticals?
Unlock access to Lifewise Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Lifewise Medsolutions Private LimitedActive 5 years 4 monthsRakesh Sharma and Shruti Rana are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Idbi Bank Limited Creation Date: 18 Jan 2021 | ₹4.92 M | Open |
How Many Employees Work at Lifewise Pharmaceuticals?
Lifewise Pharmaceuticals has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lifewise Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lifewise Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
